Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for rheumatoid arthritis.

P C Taylor1, R O Williams, R N Maini

  • 1The Kennedy Institute Division, Imperial College School of Medicine, 1 Aspenlea Road, W6 8LH, London, UK.

Current Opinion in Immunology
|September 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.

Scandinavian journal of rheumatology·2023
Same author

Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study.

Scandinavian journal of rheumatology·2021
Same author

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.

RMD open·2020
Same author

ARCTIC CHANGE AND POSSIBLE INFLUENCE ON MID-LATITUDE CLIMATE AND WEATHER: A US CLIVAR White Paper.

US CLIVAR reports·2019
Same author

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

Annals of the rheumatic diseases·2016
Same author

Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.

Clinical and experimental immunology·2015
Same journal

Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking.

Current opinion in immunology·2026
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
Same journal

On or within: spatial determinants of antigen handling in the nasal turbinates.

Current opinion in immunology·2026
Same journal

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
See all related articles

Long-term use of anti-tumor necrosis factor (TNF) therapies provides sustained symptom relief and improves quality of life for rheumatoid arthritis (RA) patients. These treatments also protect joints from damage, even in patients without clear symptom improvement.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
  • Conventional disease-modifying antirheumatic drugs (DMARDs) are standard RA treatments.
  • Tumor necrosis factor-alpha (TNF-alpha) plays a key role in RA pathogenesis.

Purpose of the Study:

  • To evaluate the long-term efficacy of anti-TNF-alpha biological agents in rheumatoid arthritis.
  • To assess the impact of anti-TNF therapy on disease symptoms, quality of life, and joint structural damage.
  • To determine the effectiveness of anti-TNF therapy in both established and early RA patients.

Main Methods:

  • Review of recently published studies on anti-TNF therapy in RA patients.

Related Experiment Videos

  • Analysis of data on symptom control, disease activity, quality of life, and radiographic joint damage.
  • Inclusion of patients with established RA, those unresponsive to conventional DMARDs, and DMARDs-naïve patients.

    • Main Results:

    • Long-term anti-TNF therapy leads to sustained improvement in RA symptoms and quality of life.
    • Anti-TNF agents demonstrate a protective effect on joint structures, irrespective of symptom control.
    • Therapeutic benefits are evident in both established and early RA populations, including DMARDs-naïve patients.

    Conclusions:

    • Anti-TNF therapies represent a new standard of care for rheumatoid arthritis, offering significant symptom control.
    • These biological agents provide crucial joint protection, a benefit observed even without apparent clinical symptom improvement.
    • Anti-TNF therapy is effective across a spectrum of RA patient profiles, from early to established disease stages.